COMP <GO>
VCEL vs JNJ // EV/EBITDA & P/E VALUATION
Vericel Corporation (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: VCEL 3
— JNJ 8
▲ EV/EBITDA & P/E VALUATION LEADER: JNJ
LAST: $42.91 (+4.43%) • MKT CAP: $2.20B
valuation
61.4x
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VCEL VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VCEL | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.40% | 67.90% | +6.50 | VCEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.40% | 25.50% | -22.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 61.4x | 18.5x | +42.90 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 1.13% | 2.97% | -1.84 | JNJ | /fcf-yield <GO> |
| Operating Margin | 4.00% | 34.70% | -30.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 6.00% | 28.50% | -22.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | 6.00% | +10.50 | VCEL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.94 | 5.59 | +4.35 | VCEL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.2 | 62.1 | -15.94 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 111.7x | 23.0x | +88.70 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.20B | $662.49B | -$660.29B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VCEL REV | JNJ REV | VCEL GROSS % | JNJ GROSS % | VCEL FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $276.3M | $94.19B | 74.4% | 67.9% | $24.7M | $19.70B |
| FY 2024 | $237.2M | $88.82B | 72.6% | 69.1% | -$5.8M | $19.84B |
| FY 2023 | $197.5M | $85.16B | — | — | $35.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VCEL // BETA —
JNJ // BETA 1.08